secwatch.observer — SEC 8-K summary
======================================

Issuer:     INTENSITY THERAPEUTICS, INC. (INTS)
CIK:        0001567264
Form:       8-K
Filed at:   2024-03-14T23:59:59+00:00
Accession:  0001628280-24-011219
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Intensity Therapeutics FY 2023 net loss $10.5M; cash $14.8M funds ops through Q1 2025
--------------------------------------------------------------------------------

- Net loss $10.5M in 2023 vs $7.6M in 2022; includes $2.3M non-cash loss on debt conversion.
- Year-end cash & investments $14.8M; company expects runway to end of Q1 2025.
- R&D expenses $4.8M (vs $5.1M); G&A $3.5M (vs $2.4M) due to public-company costs.
- Phase 3 sarcoma trial (INVINCIBLE-3) targeting 333 patients, overall survival endpoint; enrollment starts mid-2024.
- Phase 2/3 breast cancer program (INVINCIBLE-4) to begin mid-2024; endpoint pathological complete response rate.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1567264/000162828024011219/0001628280-24-011219-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1567264/000162828024011219/intensity-20240314.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-011219

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer